Table of contents

From the horses mouth

Bio-n-Tech Investors update 2021

https://investors.biontech.de/static-files/7e72deb1-ef94-4898-9a2e-280d674a4666

BioNTech and Pfizer are also planning studies to further evaluate the vaccine in people with compromised immune systems.
BioNTech and Pfizer will start a Phase 3 trial to evaluate the safety, tolerability and immunogenicity of lyophilized BNT162b2 presented in single-dose vials and of frozen liquid
BNT162b2 in multidose vials. This trial will also assess the non-inferiority of the lyophilized formulation. The trial will be conducted in healthy adults 18 through 55 years of age
and will start in the United States in April. We expect data from this trial in the third quarter of 2021.